Coherus Biosciences Inc., of Redwood City, Calif., said its biosimilar, Udenyca (pegfilgrastim-cbqv), had preliminary unaudited net sales for the quarter that ended March 31 that are expected to be in the range of $36 million to $38 million. The drug gained FDA approval late last year.